drugset / Trial / NCT00741884
A Study to Evaluate the Safety and Efficacy of Three Doses of a Controlled Release Formulation of Varenicline for Smoking Cessation
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, efficacy, and tolerability of twice daily (BID) administration of three dose strengths (1.2 mg, 1.8 mg, and 2.4 mg) of varenicline controlled release (CR) tablets in adult smokers.
Timeline
- Start
- 2010-08
- Primary completion
- 2011-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Varenicline | Small molecule | 1 mg | — |
| Subject | Varenicline | Small molecule | 1.2 mg | — |
| Subject | Varenicline | Small molecule | 1.8 mg | — |
| Subject | Varenicline | Small molecule | 2.4 mg | — |
Indications
No indication recorded.